NeuBase Therapeutics (NeuBase Therapeutics) 3-Year Book Growth Rate : 0.00% (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics 3-Year Book Growth Rate?

NeuBase Therapeutics's Book Value per Share for the quarter that ended in Sep. 2023 was $2.45.

During the past 12 months, NeuBase Therapeutics's average Book Value per Share Growth Rate was -82.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of NeuBase Therapeutics was 108.80% per year. The lowest was -86.10% per year. And the median was -14.25% per year.

Competitive Comparison of NeuBase Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, NeuBase Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuBase Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's 3-Year Book Growth Rate falls into.

NeuBase Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

NeuBase Therapeutics (NAS:NBSE) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

NeuBase Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

O7P:Germany O7P:Germany

Address

350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219

Website

https://www.neubasetherapeutics.com

NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

Executives

Symetryx Corp	10 percent owner	2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff	10 percent owner	461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff	10 percent owner	461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann	officer: COO	700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende	director	C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro	officer: Chief Medical Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei	officer: See Remarks	350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall	director	350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw	officer: Chief Scientific Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles	director	2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast	director
Dietrich A Stephan	director, 10 percent owner, officer: President and CEO	213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc	10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801